“A lot of headwinds, unfortunately. Very few tailwinds. The…” — The a16z Show at 48:34
“A lot of headwinds, unfortunately. Very few tailwinds. The pharmaceutical problems are actually taking a hit from MFN. The regulators, like, at the CBER, they were just, like, approving designs and then going back and not approving the actual trial results when it got done. That's chaotic. It hurts the ability of…”
0:00
57:43